Moderna (MRNA) Eyes FDA Advisory Panel Review for mRNA Flu Vaccine mFlusiva

The U.S. Food and Drug Administration released positive briefing documents ahead of a June 18 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting to assess the benefit-risk profile of Moderna's (NASDAQ: MRNA) mRNA-based seasonal flu vaccine, mFlusiva. The FDA's documents set the stage for a pivotal regulatory review that could open a new commercial category for the company beyond its established COVID-19 franchise. Moderna stock gained 6.27% on Tuesday, June 16, 2026, closing at $55.40.

VRBPAC Review and Pipeline Context

• The FDA's VRBPAC is scheduled to meet on June 18, 2026, to evaluate the benefit-risk profile of mFlusiva, Moderna's mRNA seasonal influenza vaccine candidate.
• The FDA released briefing documents ahead of that meeting, which investors interpreted as a constructive signal for the candidate's regulatory path, according to news reports.
• Moderna has indicated it is targeting the launch of three new vaccines over the next two years, per company statements reported in the news.
• Moderna separately announced it will host an Investor Event, Science Day, on June 25, 2026, at 9:00 a.m. ET in Cambridge, MA, featuring an overview of the company's research pipeline.

Why It Matters

A favorable VRBPAC recommendation would represent a meaningful regulatory milestone for mFlusiva, potentially positioning Moderna's mRNA platform in the large seasonal influenza vaccine market. The committee's review is an advisory step; final FDA approval would be a separate decision, but positive advisory panel outcomes historically carry significant weight in the agency's evaluation process.

The broader context of three planned vaccine launches over two years, as described in company statements, suggests Moderna is working to diversify its revenue base beyond COVID-19 products. The June 25 Science Day event is expected to provide additional detail on the research programs underpinning that pipeline ambition.

Wall Street View

Wall Street's current consensus on Moderna skews cautious: as of June 1, 2026, analyst ratings show 4 Buy recommendations, 19 Holds, 4 Sells, and 3 Strong Sells, with no Strong Buy ratings. That compares to a prior period in May 2026 where 2 Strong Buys and 7 Buys were on record, indicating a net downward drift in conviction among covering analysts even as near-term catalysts have emerged.

Investor Takeaway

The FDA's release of positive briefing documents ahead of the June 18 VRBPAC meeting on mFlusiva is the specific catalyst behind Tuesday's 6.27% move, and the outcome of that advisory committee session will be closely watched as a signal for mFlusiva's approval prospects. With Science Day scheduled for June 25 and three vaccine launches reportedly targeted over the next two years, the next two weeks carry a high density of potential catalysts for MRNA shareholders. The predominantly Hold-weighted analyst consensus suggests the street is waiting for regulatory and commercial clarity before shifting its view.